Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds

Advertising today archive

2260 PWToday Stories


28 Jun 16

Bioven, the late-stage biopharmaceutical company focused on cancer, is pleased to announce that it has secured an option to exclusive US marketing rights to EGF-PTI, a novel immunotherapy which the Company is currently progressing in an international, pivotal Phase III trial in non-small cell lung cancer (NSCLC).

Bioven earlier this year filed an updated Investigational New Drug application with the US Food & Drug Administration so that US study centres can be included in its current Phase III trial. 

The option to exclusive US rights was granted by Cuba’s CIMAB SA, which has already granted exclusive rights to Bioven for territories in Europe, ASEAN and Australasia along with the first right of refusal in the Middle East.

Dr Agustin Lage, President of CIMAB SA, commented: “We have been working closely with Bioven since 2005 on the international roll-out of our exciting lung cancer treatment. We believe that this treatment, initially developed at the Centre of Molecular Immunology (CIM) and for which CIMAB SA is entitled to grant licences worldwide, is a major breakthrough for lung cancer sufferers and we are excited that Bioven is progressing it through an international Phase III trial. We were therefore pleased to grant Bioven a 12 month option period for exclusive US marketing rights.”

Bioven has made an initial payment to CIMAB SA to secure the option, which will be exercised by the payment of a further instalment. 

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.